Standards, options and recommendations (SOR) for the clinical use of erythropoeitin in oncology;Standards, options et recommandations pour l'utilisation de l'erythropoietine en cancerologie

Bulletin du Cancer

Volumn 85, Issue 4, 1998, Pages 337-346

  Spaeth D ^a,c   Marchal, C ^a   Blanc Vincent, M P ^b  

^a CENTRE ALEXIS VAUTRIN   (France)

^b INSTITUT BERGONIÉ   (France)

^c FNCLCC   (France)

Author keywords

Anemia; Cancer; Chemotherapy; Epoietin alpha; Epoietin beta; Erythropoietin; Guidelines; Neoplasms; Radiotherapy; Recombinant human erythropoietin

Indexed keywords

ERYTHROPOIETIN;

ARTICLE; BONE MARROW SUPPRESSION; CANCER; CANCER CHEMOTHERAPY; CLINICAL PROTOCOL; FRANCE; HUMAN; STANDARD; TREATMENT INDICATION;

ANEMIA; ANTINEOPLASTIC AGENTS; BLOOD TRANSFUSION; ERYTHROPOIETIN, RECOMBINANT; HUMANS; RANDOMIZED CONTROLLED TRIALS;

EID: 0031814704     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Abels RI, Larholt KM, Krantz KD, et al. Recombinant human erythropoietin for the treatment of anaemia of cancer. In: Murphy MJ, editor. Blood cell growth factors: their present and future use in haematology and oncology. Dayton (Ohio): Alpha Medical Press, 1991; 121-41.
2. Abels RI. Recombinant human erythropoietin in the treatment of the anaemia of cancer. Acta Haematol 1992; 87 (suppl. 1): 4-11.
3. Abels R. Erythropoietin for anaemia in cancer patients. Eur J Cancer 1993; 29A (suppl. 2): S2-8.
4. Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 1990; 87: 5978-82.
5. Beck MN, Beck D. Recombinant erythropoietin in acute chemotherapy-induced anemia of children with cancer. Med Pediatr Oncol 1995; 25: 17-21.
6. Berdel WE, Koenigsmann N, Papadimitrion CA. Effects of erythropoietin without or in combination with IL3, GM-CSF or G-CSF on the growth of human non-hematopoietic tumor cells in vitro. Clin Invest 1994; 72: Abstract B70.
7. Bolonaki I, Stiakaki E, Lydaki E, Dimitriou H, Kambourakis A, Kalmantis T, et al. Treatment with recombinant human erythropoietin in children with malignancies. Pediatr Hematol Oncol 1996; 13: 111-21.
8. Bosze P, Mayer A, Thurzo E, Kiss A, Rak K, Stumpf J. Recombinant human erythropoietin in the treatment of anemic patients undergoing chemotherapy for cancer. Orv Hetil 1995; 136: 2567-72.
9. Brunson ME, Alexander JW. Mechanisms of transfusion-induced immunosuppression. Transfusion 1990; 30: 651-8.
10. Bush RS, Jenkin RD, Allt WE, et al. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer 1978; 37: 302-6.
11. Canetta R, Rozencweig M, Carter SK. Carboplatin: the clinical spectrum to date. Cancer Treat Rev 1985; 12 (suppl. A): 125-36.
12. Cascinu S, Fedeli A, Del Ferro E, Luzi Fedeli S, Catalano G. Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J Clin Oncol 1994; 12: 1058-62.
13. Cascinu S, Del Ferro E, Fedeli A, Ligi M, Alessandroni P, Catalano G. Recombinant human erythropoietin treatment in elderly cancer patients with cisplatin-associated anemia. Oncology 1995; 52: 422-6.
14. Case DC Jr, Bukowski RM, Carey RW, Fishkin EH, Henry DH, Jacobson RJ, et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 1993; 85: 801-6.
15. Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enllerziegler L, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood 1995; 86: 4446-53.
16. Crawford J, Blackwell S, Shoemaker D, Pupa MR, Sparrow T, Herndon J, et al. The prophylactic role of recombinant human erythropoietin (rHuEPO) in reducing chemotherapy-related anemia in patients with small cell lung cancer (SCLC) receiving cyclophosphamide, doxorubicin, and etoposide (CAE) chemotherapy with G-CSF support. Proc Am Soc Clin Oncol 1994; 13: Abstract 1586, 458.
17. Croockewit AJ, Bronchud MH, Aapro MS, Bargetzi MJ, Crown J, Gratwohl A, et al. A european perspective on haematopoietic growth factors in haemato-oncology: report of an expert meeting of the EORTC. Eur J Cancer 1997; 33: 1732-46.
18. Dainiak N, Kulkarni V, Howard D, Kalmanti M, Dewey MC, Hoffman R. Mechanisms of abnormal erythropoiesis in malignancy. Cancer 1983; 51: 1101-6.
19. de Campos E, Radford J, Steward W, Milroy R, Dougal M, Swindell R, et al. Clinical and in vitro effects of recombinant human erythropoictin in patients receiving intensive chemotherapy for small-cell lung cancer. J Clin Oncol 1995; 13: 1623-31.
20. Del Mastro L, Venturini M, Garrone O, Sertoli MR, Pasquetti W, Pastorino S, et al. Erythropoietin in the prevention of chemotherapy induced anemia: results from randomized trial in early breast cancer patients. Proc Am Soc Clin Oncol 1995; 14: Abstract 697, 256.
21. Denton TA, Diamond GA, Matloff JM, Gray RJ. Anemia therapy: individual benefit and societal cost. Semin Oncol 1994; 21 (2 suppl. 3): 29-35.
22. Dische S. Radiotherapy and anaemia - the clinical experience. Radiother Oncol 1991; 20 (suppl. 1): 35-40.
23. Dusenbery KH, McGuire WA, Holt PJ, Carson LF, Fowler JM, Twiggs LB, et al. Erythropoietin increases hemoglobin during radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys 1994; 29: 1079-84.
24. Evans JC, Bergsio P. The influence of anemia on the results of radiotherapy in carcinoma of the cervix. Radiology 1965; 84: 709-17.
25. Falkson CI, Keren Rosenberg S, Uys A, Falkson C, Stevens K, Vermaak WJ. Recombinant human erythropoietin in the treatment of cancer-related anaemia. Oncology 1994; 51: 497-501.
26. Fervers R, Bonichon F, Demard F, Héron JF, Mathoulin S, Philip T, et al. Méthodologie de développement des standards, options et recommandations diagnostiques et thérapeutiques en cancérologie. Bull Cancer 1995; 82: 761-7.
27. Francis DM. Relationship between blood transfusion and tumour behaviour. Br J Surg 1991; 78: 1420-8.
28. Gamucci T, Thorel MF, Frasca AM, Giannarell D, Calabresi F. Erythropoietm for the prevention of anaemia in neoplastic patients treated with cisplatin. Eur J Cancer 1993; 29A (suppl. 2): S13-4.
29. Gebbia V, Gebbia N, Testa N, et al. Subcutaneous recombinant human erythropoietin prevents chemotherapy-related anemia in patients with advanced cancer. Int J Oncol 1992; 1: 341-5.
30. Gordon LI, Harrington D, Andersen J, Colgan J, Glick J, Neiman R, et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma [see comments]. N Engl J Med 1992; 327: 1342-9.
31. Guichard M, Lartigau E. L'effet oxygène : bilan des connaissances et applications pratiques. Bull Cancer/Radiother 1991; 78: 441-53.
32. Henry DH, Abels RI. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies. Semin Oncol 1994; 21 (2 suppl. 3): 21-8.
33. Hirst DG. Anemia: a problem or an opportunity in radiotherapy? Int J Radiat Oncol Biol Phys 1986; 12: 2009-17.
34. Lavey RS, Dempsey WH. Erythropoietin increases hemoglobin in cancer patients during radiation therapy. Int J Radiat Oncol Biol Phys 1993; 27: 1147-52.
35. Leitgeb C, Pecherstorfer M, Fritz E, Ludwig H. Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer 1994; 73: 2535-42.
36. Ludwig H, Fritz H, Leitgeb C, Krainer M, Kuhrer I, Sagaster P, et al. Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors. Ann Oncol 1993; 4161-7.
37. Ludwig H, Pecherstorfer M, Leitgeb C, Fritz E. Recombinant human erythropoietin for the treatment of chronic anemia in multiple myeloma and squamous cell carcinoma. Stem Cells Dayt 1993; 11: 348-55.
38. Ludwig H, Fritz H, Leitgeb C, Pecherstorfer M, Samonigg H, Schuster J. Prediction of response to erythropoietin treatment in chronic anemia of cancer [see comments]. Blood 1994; 84: 1056-63.
39. Ludwig H, Sundal E, Pecherstorfer M, Leitgeb C, Bauernhofer T, Beinhauer A, et al. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy. Cancer 1995; 76: 2319-29.
40. Madura JA. Use of erythropoietin and parenteral iron dextran in a severely anemic Jehovah's Witness with colon cancer. Arch Surg 1993; 128: 1168-70.
41. Markman M, Reichman B, Hakes T, Rubin S, Jones W, Lewis JL Jr, et al. The use of recombinant human erythropoietin to prevent carboplatin-induced anemia. Gynecol Oncol 1993; 49: 172-6.
42. Masuda S, Nagao M, Takahata K, Konishi Y, Gallyas F Jr, Tabira T, et al. Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J Biol Chem 1993; 268: 11208-16.
43. Miller CB, Platanias LC, Mills SR, Zahurak ML, Ratain MJ, Ettinger DS, et al. Phase I-II trial of erythropoietin in the treatment of cisplatin-associated anemia. J Natl Cancer Inst 1992; 84: 98-103.
44. Miller CB, Mills SR. Anemia associated with cisplatin chemotherapy. In: Mauer C, et al. editors. Erythropoietin: molecular physiology and clinical applictions. New York: Marcel Dekker, 1993; 299-308.
45. Okuno Y, Takahashi T, Suzuki A, Ichiha S, Nakumura K, Hitomi K, et al. Expression of the erythropoietin receptor on a human myeloma cell line. Biochem Biophys Res Commun 1990; 170: 1128-34.
46. Overgaard J, Hansen HS, Jorgensen K, Hjelm Hansen M. Primary radiotherapy of larynx and pharynx carcinoma - an analysis of some factors influencing local control and survival. Int J Radiat Oncol Biol Phys 1986; 12: 515-21.
47. Platanias LC, Miller CB, Mick R, Hart RD, Ozer H, McEvilly JM, et al. Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients. J Clin Oncol 1991; 9: 2021-6.
48. Rosti V, Pedrazzoli P, Ponchio L, Zibera C, Novella A, Lucotti C, el al. Effect of recombinant human erythropoietin on hematopoietic and non-hematopoietic malignant cell growth in vitro. Haematologica 1993; 78: 208-12.
49. Rustowski J, Kups W. Factor influencing the results of radiotherapy in cases of inoperable endometrial cancer. Gynecol Oncol 1982; 14: 185-93.
50. Schreiner P, Siracka E, Siracky J, Manka I. The effect of anemia on the radiotherapy results of the uterine cervix cancer. Neoplasma 1975; 22: 655-60.
51. Smith DH, Goldwasser K, Vokes EE. Serum immunoerythropoietin levels in patients with cancer receiving cisplatin-based chemotherapy. Cancer 1991; 68: 1101-5.
52. Taylor JE, Henderson IS, Stewart WK, Belch JJ. Erythropoietin and spontaneous platelet aggregation in haemodialysis patients. Lancet 1991; 338: 1361-2.
53. Ten Bokkel Huinink WW, van Tinteren H, Valkenet L, Dalesio O, Ehmer B. Treatment of platinum induced anemia in ovarian cancer patients: a controlled scudy with erythtopoietin to prevent anemia and transfusions. Proc Am Soc Clin Oncol 1994; 13: Abstract 720, 234.
54. Thatcher N. Controlled study of the efficacy and safety of r-Hu erythropoietin in the prevention of anaemia in patients with small cell lung cancer receiving chemotherapy. Proc Int Soc Hematol 1994; 188: Abstract A15.
55. Tsukuda M, Mochimatsu I, Nagahara T, Kokatsu I, Sawaki S, Kubota A, et al. Clinical application of recombinant human erythropoietin tor treatments in patients with head and neck cancer. Cancer Immunol Immunother 1993; 36: 52-6.
56. Vigario G, Kurohara SS, George FW. Association of hemoglobin levels before and during radiotherapy with prognosis in uterine cervix cancer. Radiology 1973; 106: 649-52.
57. Vijayakumar S, Roach M, 3d, Wara W, Chan SK, Ewing C, Rubin S, et al. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: preliminary results of a randomized, open-labeled, phase II trial. Int J Radiat Oncol Biol Phys 1993; 26: 721-9.
58. Welch RS, James RD, Wilkinson PM, Belli F, Cowan RA. Recombinant human erythropoietin and platinum based chemotherapy in metastatic ovarian carcinoma. Proc Am Soc Clin Oncol 1993; 12: Abstract 804, 254.
59. Wood PA, Hrushesky WJ. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest 1995; 95: 1650-9.
60. Wurnig C, Windhager R, Schwameis E, Kotz R, Zoubek A, Stockenhuber F, et al. Prevention of chemotherapy-induced anemia by the use of erythropoietin in patients with primary malignant bone tumors (a double-blind, randomized, phase III study). Transfusion 1996; 36: 155-9.
61. Zucker S. Anemia in cancer. Cancer Invest 1985; 3: 249-60.